Stephan Simons, MD
Internal Medicine · Bronx, NYNPI 1710928304
Payments from drug & device makers
Across 227 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$853
- GSK$729
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$623
- AstraZeneca$385
- Amgen$243
- Pfizer$235
- plus $1K from 16 others
What the payments were for
- Food & beverage$4,062100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 42 | $853 |
| GSK | 49 | $729 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 33 | $623 |
| AstraZeneca | 24 | $385 |
| Amgen(2 entities) | 14 | $243 |
| Pfizer | 14 | $235 |
| Abbott | 9 | $202 |
| AbbVie | 9 | $185 |
| Exact Sciences | 6 | $126 |
| Mylan Specialty L.p. | 4 | $86 |
| Boehringer Ingelheim | 4 | $75 |
| Sanofi-aventis U.S. LLC | 4 | $63 |
| Astellas Pharma US Inc | 2 | $49 |
| Lilly USA, LLC | 3 | $46 |
| E.r. Squibb & Sons, L.L.C. | 2 | $44 |
| Amarin Pharma, Inc. | 2 | $33 |
| Nestle Healthcare Nutrition Inc. | 1 | $23 |
| Renalytix AI, Inc. | 1 | $20 |
| Circassia Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Phadia US Inc. | 1 | $13 |
| Vifor Pharma, Inc. | 1 | $13 |
How this compares
$4,076 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 201 | $154,898 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 166 | $131,787 |
| OzempicSemaglutide | 79 | $87,777 |
| JanuviaSitagliptin Phosphate | 78 | $68,112 |
| FarxigaDapagliflozin Propanediol | 87 | $67,222 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 72 | $51,856 |
| TrulicityDulaglutide | 29 | $41,657 |
| RybelsusSemaglutide | 32 | $40,158 |
| EliquisApixaban | 39 | $32,467 |
| MounjaroTirzepatide | 31 | $31,619 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $27,952 |
| Diclofenac Sodium | 100 | $24,810 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 25 | $24,462 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 521 | $17,477 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 32 | $13,583 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $75 | $181,071243 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $729 | $165,443241 claims |
| Novo NordiskOzempic, Rybelsus | $853 | $127,935111 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $385 | $124,427173 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $46 | $73,27660 claims |
| PfizerEliquis | $235 | $32,46739 claims |
| AbbVieLinzess | $185 | $10,11320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Bronx
- Benjamin GartrellBronx$6.3M
- David SteinBronx$2.4M
- Haiying ChengBronx$1.7M
- Jason LeiderBronx$1.4M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.